ProCE Banner Activity

Selecting and Sequencing New Treatment Strategies in Gynecologic Cancers

Conference Coverage
Clinical Thought
Two expert gynecologic oncologists answer frequently asked questions on the optimal use of new therapies in patients with endometrial, ovarian, and cervical cancer.

Released: July 05, 2022

Expiration: July 04, 2023

No longer available for credit.

Share

Faculty

Jubilee Brown

Jubilee Brown, MD

Professor and Division Director
Gynecologic Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Elisabeth Diver

Elisabeth Diver, MD

Clinical Assistant Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Stanford University
Stanford Cancer Institute
Stanford University Hospital and Clinics
Stanford, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Karyopharm Therapeutics Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Jubilee Brown, MD

Professor and Division Director
Gynecologic Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Jubilee Brown, MD: researcher: Olympus, Tesaro/GlaxoSmithKline.

Elisabeth Diver, MD

Clinical Assistant Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Stanford University
Stanford Cancer Institute
Stanford University Hospital and Clinics
Stanford, California

Elisabeth Diver, MD: consultant: EMD Serono, GlaxoSmithKline; researcher: Aravive, EMD Serono, GlaxoSmithKline.